title: Adverse drug reaction reporting in a multicenter surveillance study.
abstract: OBJECTIVE
  To evaluate the performance of a multicenter, prospective surveillance program in identifying adverse events, and to seek explanations for misclassification bias.
  
  
  METHODS
  The design was a prospective observational study of patients with documented or suspected bacterial pneumonia.
  
  
  METHODS
  Data were collected in 74 acute care hospitals across the US.
  
  
  METHODS
  This evaluation was based on a consecutive sample of 1822 adult patients (> 18 years of age) with documented or suspected bacterial pneumonia who were being treated with a cephalosporin, a penicillin, or an aminoglycoside over a 3-month period. Patients were followed for the duration of antibiotic therapy and were excluded if antibiotic therapy was < 3 days or if the pneumonia was judged to be nonbacterial.
  
  
  METHODS
  Clinical pharmacists documented patient demographics, concurrent illnesses and medications, antibiotic administration, relevant laboratory data, and the occurrence of nephrotoxicity and neutropenia.
  
  
  METHODS
  Validity of investigators' identification of neutropenia and nephrotoxicity as compared with objective laboratory data was assessed by using sensitivity, specificity, and positive and negative predictive value measures.
  
  
  RESULTS
  Among the 1502 patients with sufficient data to evaluate neutropenia, there was agreement in 1270 patients (84.6%); likewise, among 1291 patients with sufficient data to evaluate nephrotoxicity there was agreement in 1186 patients (91.9%). Sensitivity of the researchers' assessments was 50.9% and 71.0% for neutropenia and nephrotoxicity, respectively. The negative predictive value was > 95% for both events.
  
  
  CONCLUSIONS
  Overall, this evaluation demonstrated that the Drug Surveillance Network can successfully identify targeted adverse events. Moreover, this study highlights the importance of validation for all types of outcomes-oriented research studies.
authors.affiliation: Department of Pharmacy, Mary Imogene Bassett Hospital, Coopertown, NY, USA.
authors.forename: E G
authors.initials: EG
authors.lastname: Timm
authors.forename: L S
authors.initials: LS
authors.lastname: Welage
authors.forename: C A
authors.initials: CA
authors.lastname: Walawander
authors.forename: J F
authors.initials: JF
authors.lastname: Sayers
authors.forename: E L
authors.initials: EL
authors.lastname: Karpiuk
authors.forename: T D
authors.initials: TD
authors.lastname: Davis
authors.forename: T H
authors.initials: TH
authors.lastname: Grasela
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards*; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009503:Neutropenia / Q000139:chemically induced; D010607:Pharmacy Service, Hospital; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011159:Population Surveillance; D015397:Program Evaluation; D011446:Prospective Studies; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents